Cytokinetics, Incorporated
Stock Forecast, Prediction & Price Target

Cytokinetics, Incorporated (CYTK) stock Price Target by analysts

Last Year
Average Price Target

$120

Potential upside: 210.15%

Based on 1 analysts

Cytokinetics, Incorporated price prediction

Strike.market

What is Cytokinetics, Incorporated stock analysts` prediction?

Cytokinetics, Incorporated stock forecast: Based on 1 Wall Street analysts` predicted price targets for Cytokinetics, Incorporated in the last 3 months, the avarage price target is $120, with a high forecast of $NaN. The average price target represents a 210.15% change from the last price of $38.69.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Cytokinetics, Incorporated stock Price Target by analysts

Full breakdown of analysts given Cytokinetics, Incorporated price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Joseph Pantginis
H.C. Wainwright
33.33%
1/3
11 months ago $120 210.15% upside $55.28 StreetInsider
Previous targets (2)
Paul Choi
Goldman Sachs
0%
0/1
about 1 year ago $60 55.07% upside $54.56 StreetInsider
Previous targets (0)
Yasmeen Rahimi
Piper Sandler
50%
1/2
about 1 year ago $107 176.55% upside $53.21 StreetInsider
Previous targets (1)
Mayank Mamtani
B.Riley Financial
0%
0/1
over 1 year ago $92 137.78% upside $48.7 StreetInsider
Previous targets (0)
Jason Butler
JMP Securities
0%
0/2
over 1 year ago $78 101.60% upside $48.3 TheFly
Previous targets (1)
Carter Gould
Barclays
50%
1/2
over 1 year ago $95 145.54% upside $59.23 TheFly
Previous targets (1)
Joseph Pantginis
H.C. Wainwright
33.33%
1/3
over 1 year ago $90 132.61% upside $48.71 TheFly
Previous targets (2)
Serge Belanger
Needham
0%
0/1
over 1 year ago $72 86.09% upside $59.23 TheFly
Previous targets (0)
Akash Tewari
Jefferies
0%
0/1
over 1 year ago $85 119.69% upside $59.23 StreetInsider
Previous targets (0)
Justin Kim
Oppenheimer
0%
0/1
over 1 year ago $106 173.97% upside $65.27 TheFly
Previous targets (0)
Jason Butler
JMP Securities
0%
0/2
over 1 year ago $106 173.97% upside $65.27 TheFly
Previous targets (1)
Salim Syed
Mizuho Securities
0%
0/1
over 1 year ago $99 155.88% upside $72.74 StreetInsider
Previous targets (0)
Unknown
Needham
N/A
over 2 years ago $58 49.90% upside $45.59 Benzinga
N/A
Unknown
Truist Financial
N/A
over 2 years ago $60 55.07% upside $45.22 Benzinga
N/A
Dane Leone
Raymond James
50%
1/2
about 3 years ago $63 62.83% upside $52.17 Pulse 2.0
Previous targets (1)
Yasmeen Rahimi
Piper Sandler
50%
1/2
about 3 years ago $72 86.09% upside $38.84 TheFly
Previous targets (1)
Joseph Pantginis
H.C. Wainwright
33.33%
1/3
over 3 years ago $75 93.84% upside $39.87 Pulse 2.0
Previous targets (2)
Carter Gould
Barclays
50%
1/2
over 3 years ago $52 34.40% upside $39.5 TipRanks Contributor
Previous targets (1)
Dane Leone
Raymond James
50%
1/2
almost 4 years ago $54 39.57% upside $40.73 StreetInsider
Previous targets (1)
Jeffrey Hung
Morgan Stanley
100%
1/1
almost 4 years ago $45 16.30% upside $38.01 StreetInsider
Previous targets (0)

Cytokinetics, Incorporated Financial Estimates

Cytokinetics, Incorporated Revenue Estimates

Cytokinetics, Incorporated EBITDA Estimates

Cytokinetics, Incorporated Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$70.42M
 
N/A
$94.58M
 
34.30%
$7.53M
 
-92.03%
Avg: $72.93M
Low: $4.77M
High: $267.01M
avg. 868.53%
Avg: $383.80M
Low: $23.15M
High: $1.21B
avg. 426.25%
Avg: $903.98M
Low: $54.53M
High: $2.86B
avg. 135.53%
Avg: $1.55B
Low: $93.92M
High: $4.94B
avg. 72.21%
Net Income
 
% change YoY
$-242.37M
 
N/A
$-402.55M
 
-66.08%
$-526.24M
 
-30.72%
Avg: $-494.03M
Low: $-588.79M
High: $-258.68M
avg. 6.12%
Avg: $-317.72M
Low: $-569.49M
High: $-4.32M
avg. 35.68%
Avg: $35.39M
Low: $-7.84M
High: $135.42M
avg. 111.13%
Avg: $332.62M
Low: $-73.69M
High: $1.27B
avg. 839.80%
EBITDA
 
% change YoY
$-185.98M
 
N/A
$-312.86M
 
-68.22%
$-456.68M
 
-45.97%
Avg: $-72.93M
Low: $-267.01M
High: $-4.77M
avg. 84.03%
Avg: $-383.80M
Low: $-1.21B
High: $-23.15M
avg. -426.25%
Avg: $-903.98M
Low: $-2.86B
High: $-54.53M
avg. -135.53%
Avg: $-1.55B
Low: $-4.94B
High: $-93.92M
avg. -72.21%
EPS
 
% change YoY
-$3.15
 
N/A
-$4.48
 
-42.22%
-$5.45
 
-21.65%
Avg: -$4.42
Low: -$6.1
High: -$2.68
avg. 18.95%
Avg: -$2.73
Low: -$5.9
High: -$0.04
avg. 38.11%
Avg: $0.37
Low: -$0.08
High: $1.4
avg. 113.41%
Avg: $3.45
Low: -$0.76
High: $13.19
avg. 839.80%
Operating Expenses
 
% change YoY
$96.80M
 
N/A
$177.97M
 
83.85%
$173.61M
 
-2.45%
Avg: $419.09M
Low: $27.44M
High: $1.53B
avg. 141.39%
Avg: $2.20B
Low: $133.06M
High: $7.00B
avg. 426.25%
Avg: $5.19B
Low: $313.40M
High: $16.48B
avg. 135.53%
Avg: $8.94B
Low: $539.73M
High: $28.39B
avg. 72.21%

FAQ

What is Cytokinetics, Incorporated stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 248.18% in 2025-2028.

We have gathered data from 13 analysts. Their low estimate is -588.79M, average is -494.03M and high is -258.68M.

What is Cytokinetics, Incorporated stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 375.63% in 2025-2028.

We have gathered data from 13 analysts. Their low revenue estimate is $4.77M, average is $72.93M and high is $267.01M.

What is Cytokinetics, Incorporated stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 252.57% in 2025-2028.

We have gathered data from 13 analysts. Their low earnings per share estimate is -$6.1, average is -$4.42 and high is $-2.68.

What is the best performing analyst?

In the last twelve months 1 analysts have been covering Cytokinetics, Incorporated stock. The most successful analyst is Joseph Pantginis whose win rate is 33.33%. He has correctly predicted 1/3 price targets.